touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes.
His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY’ was given at UEG Week Virtual, 3-5 Oct 2021.
- What are the advantages of the Partial Mayo Clinic Score (pMCS) as an outcome measure in clinical trials for ulcerative colitis? (0:17)
- What were the aims and design of the SELECTION study? (1:42)
- What were the findings in terms of pMCS? (3:07)
- What are the clinical implications of these findings, and where do you see filgotinib sitting in the treatment paradigm for UC? (3:46)
Disclsoures: Dr Marc Ferrante has received grants from Amgen, Biogen, Janssen, Pfizer and Takeda; personal fees from, Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Eli Lilly, Medtronic, MSD, Mylan, Pfizer, Sandoz, Takeda, Thermo Fisher and Truvion Healthcare and non-financial support from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Lilly, Medtronic, MSD, Mylan, Pfizer, Sandoz, Takeda, Thermo Fisher and Truvion Healthcare.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of UEG Week Virtual, 3-5 Oct 2021.
Share this Video
Related Videos In Gastroenterology
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!